SCHEMBL3316807

SCHEMBL3316807

CC1(C)[C@H](COS(C)(=O)=O)C[C@@H]1CCOCc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.36
TAAR1 Q96RJ0 1/20 0.34
EPHX2 P34913 2/20 0.34
PDE4D Q08499 2/20 0.34
AGTR2 P50052 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
TSHR P16473 1/20 0.33
LMNA P02545 2/20 0.32
MMP1 P03956 1/20 0.32
MMP2 P08253 1/20 0.32
MMP3 P08254 1/20 0.32
MMP9 P14780 1/20 0.32
MMP13 P45452 1/20 0.32
PKM P14618 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
GAA P10253 1/20 0.31
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3318768 0.90 TAAR1 (0.37) ALDH1A1TAAR1EPHX2PDE4DAGTR2
SCHEMBL3317951 0.87 MMP1 (0.36) ALDH1A1TAAR1EPHX2PDE4DAGTR2
SCHEMBL29050773 0.75 PDE4D (0.44) ALDH1A1TAAR1EPHX2PDE4DAGTR2
SCHEMBL30051811 0.75 PDE4D (0.44) ALDH1A1TAAR1EPHX2PDE4DAGTR2
SCHEMBL30052193 0.75 PDE4D (0.44) ALDH1A1TAAR1EPHX2PDE4DAGTR2
SCHEMBL3316782 0.74 LTA4H (0.48) ALDH1A1PDE4DAGTR2LMNAHTT
SCHEMBL3315476 0.74 TSHR (0.39) TAAR1PDE4DAGTR2TSHRLMNA
SCHEMBL10171982 0.73 CTSL (0.42) TAAR1AGTR2CA1CA2CA9
SCHEMBL17407792 0.73 TSHR (0.41) TAAR1AGTR2CA1CA2CA9
SCHEMBL3316138 0.73 LTA4H (0.47) ALDH1A1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2066648-B1 SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS ESTEVE LABOR DR (ES) 2017-04-12 EP disclosed
US-20100105680-A1 SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2010-04-29 US disclosed
EP-2066648-A1 SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS Laboratorios Del. Dr. Esteve, S.A. (ES) 2009-06-10 EP disclosed
WO-2008015266-A1 SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2008-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105680-A1 SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS SIGMAR1, TMEM97, OPRK1 ALDH1A1 1719/4885TAAR1 64/4885EPHX2 2792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.